Navigation Links
Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP

ts receiving PROMACTA and placebo respectively. Other AEs included nausea, nasopharyngitis, diarrhea and vomiting.

About PROMACTA

PROMACTA (eltrombopag olamine) is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets, and thus can be considered a platelet growth factor.(4) The safety profile will be further examined in ongoing clinical trials. PROMACTA was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. It is being developed by GlaxoSmithKline. PROMACTA is an investigational compound that has not received regulatory approval in any market for any indication at this time.

Ongoing Trials

Several PROMACTA trials investigating the short- and long-term treatment of chronic ITP are currently open and enrolling.(5) EXTEND (Eltrombopag eXTENded Dosing Study) is an open-label study for patients who had participated in previous PROMACTA trials and wished to take PROMACTA for the long-term treatment of their chronic ITP. RAISE (RAndomized placebo controlled ITP Study with Eltrombopag) is a global, randomized, double-blind, placebo-controlled Phase III trial currently assessing the safety, efficacy and tolerability of PROMACTA in a long-term treatment setting (up to six months) involving 189 patients across 135 centers in 26 countries. REPEAT (Repeat ExPosure to Eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura) will involve 50 patients with chronic ITP and will assess the safety and efficacy of repeated administration of PROMACTA. For further information on the trials, visit http://www.itpstudy.com or http://www.clinicaltrials.gov.

About Idiopathic Thrombocytopenic Purpura'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
11. GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
Post Your Comments:
(Date:5/4/2015)... , May 4, 2015 Dyadic International, ... whose patented and proprietary technologies are used to ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... its financial results for quarter ending March 31, ... 2015 and will host a conference call that ...
(Date:5/4/2015)... May 4, 2015 Henry Schein, Inc. (NASDAQ: ... care products and services to office-based dental, animal health ... the quarter ended March 28, 2015. Net ... billion, an increase of 1.4% compared with the first ... local currencies and a 6.0% decline related to foreign ...
(Date:5/4/2015)... May 4, 2015 According to ... Scope (Rigid (Laparoscope, Ureteroscope), Flexible (Colonoscope, Gastroscope), Visualization Systems ... (Colonoscopy, Laparoscopy, Arthroscopy) - Global Forecasts to 2019 ", published ... reach $19.0 Billion by 2019 with a CAGR of ... Browse   127   ma ...
Breaking Medicine Technology:Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9Henry Schein Reports Record First Quarter Results 10Henry Schein Reports Record First Quarter Results 11Henry Schein Reports Record First Quarter Results 12Henry Schein Reports Record First Quarter Results 13Henry Schein Reports Record First Quarter Results 14Henry Schein Reports Record First Quarter Results 15Henry Schein Reports Record First Quarter Results 16Henry Schein Reports Record First Quarter Results 17The Medical Videoscope Market Worth $19.0 Billion by 2019 2The Medical Videoscope Market Worth $19.0 Billion by 2019 3The Medical Videoscope Market Worth $19.0 Billion by 2019 4The Medical Videoscope Market Worth $19.0 Billion by 2019 5
(Date:5/4/2015)... Malibu, CA (PRWEB) May 04, 2015 ... of KissSafe™ oral antiseptic breath spray. KissSafe™ is ... making kissing a safer experience while adding fresh ... that safely and effectively kills germs in the ... kissing. It also contains ingredients that possess additional ...
(Date:5/4/2015)... May 04, 2015 Leonardo J. Lozada, ... chief physician executive, and William C. Daniel, M.D., Saint ... accepted personal invitations from the Secretary of the Air ... (NSF) at the Air War College, Maxwell Air Force ... influential citizens to senior U.S. and international officers and ...
(Date:5/4/2015)... May 04, 2015 The University ... today launched a new initiative at UC Davis ... generation of physicians committed to advancing Latino health. ... Medicos, or Preparing Students to Be Physicians, (“Prep ... will provide scholarships, mentorship and internship opportunities, a ...
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... McNeil & Company , a nationwide ... coverage for its Emergency Services Insurance Program ... and proactive risk management to the emergency services industry. ... providing our customers with unparalleled service and the best ... are excited to launch over 100 new enhancements that ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3
... Food and Drug Administration (FDA) have approved the drug Femara ... breast cancer among post menopausal women//. ,Various studies ... result of these studies was published in the December 29 ... said that the Novartis drug Femara was very efficient in ...
... of swallows in Malawi had raised fears about the possibility of ... // have revealed a negative bird flu infection status of ... ,"We have tested samples that were sent to us ... swallows, which were dying in large numbers. We don't know what ...
... enterotoxin produced by the bacteria Vibrio cholerae, which leads to ... has occurred in two cities in // ... infected with the bacteria in two districts of Chikomba and ... is high in conditions where treatment is not given. The ...
... in attitudes toward circumcision in Swaziland, which has one of ... one of the highest HIV prevalence rates. ... sudden comeback in the country since the publication of a ... risk of contracting HIV. ,According to the ...
... children is a major health hazard. More-so when homes use ... lead // poisonings in children, by suggesting new requirements ... years, Lead, a highly toxic metal has been used as ... spectrum of health problems ranging from cognitive impairment and learning ...
... Kerr has urged to increase awareness of organ donation among ... loss dying // due to organ failure and non-availability ... heavy human loss of young people and their lives depend ... Donor cards and registration with NHS organ donor register, which ...
Cached Medicine News:Health News:Men queue up for Circumcision In Swaziland To Prevent HIV/AIDS 2Health News:Child-friendly initiative For Lead-Based Paint Work: EPA, USA 2
This standard tying forcep is curved with 5mm titanium coated platforms. Length 85 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson tying forceps with serrated handle, platform 4 mm and overall length of 85 mm....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Medicine Products: